Calendario›TCRX›A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease
A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease
Ensayo de TScan Therapeutics, Inc. en Autoimmune Diseases · Ulcerative Colitis · Multiple Sclerosis · Scleroderma · Ankylosing Spondylitis · Celiac Disease · Non-radiographic Axial Spondyloarthritis (Nr-axSpA) · Crohn&Amp;#39;s Disease · Birdshot Chorioretinitis (del registro, en inglés).
Más ensayos de: Enfermedades autoinmunes · Colitis ulcerosa · Esclerosis múltiple.
- Fase
- no aplica
- Estado
- Completado
- Participantes
- 238
- Centros
- 11
- Fin del objetivo primario
- sep 2026
Qué significa cada fase y cada estado.
Estudio observacional. Comenzó en ene 2023.
Lo que ha cambiado
Movimientos registrados desde que PivotalWire vigila este ensayo. Un retraso no se anuncia: se ve comparando, y esto es la comparación ya hecha.
| Visto | Qué se mueve | Cambio |
|---|---|---|
| 16 sep 2026 | Estado | Reclutando pacientes → Completado |
Qué mide
Identify peptide targets together with their associated TCRs in patients with autoimmune diseases under study. (del registro, en inglés) (3 años)
Cómo lo describe el promotor
En el documentoEn inglés, del registroThe most clinically meaningful way to discover new targets of T cells in autoimmune diseases is to study the tissues of patients with active autoimmune disease mediated organ inflammation. These tissues contain both cytotoxic and helper T cells that are driving their disease, and these T cells are being guided by TCRs that recognize tissue-specific targets. By collecting tissue when a patient has active inflammation, it is possible to determine which T cells are activated and undergoing clonal expansion in the patient's diseased organ. TScan has developed a genome-wide, high-throughput technology to determine the natural, physiological target of any TCR (Kula, 2019). The goal of this study is to isolate T cells from inflamed tissues and matched blood samples and/or matched normal tissues (for patients with inflammatory bowel diseases). T cell clones that are expanded in diseased tissues relative to blood or normal tissues will be selected and the targets of their TCRs will be defined using TScan's genome-wide, high-throughput target ID technology. The goal of this study is to discover a collection of peptide targets, along with their associated TCRs to be developed as new tolerogenic therapies for patients with autoimmune diseases.
Más ensayos de TCRX
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors | no aplica | En marcha, sin reclutar | ene 2026 (prevista, ya pasada: sin actualizar en el registro) |
| SOC + TSC-101 | Fase 1 | Reclutando pacientes | jun 2026 (real) |
| TSC-204-A0201 | Fase 1 | En marcha, sin reclutar | dic 2026 (prevista) |
| TSC-101 · ALLOHA-2 | Fase 3 | Reclutando pacientes | jun 2029 (prevista) |
| LTFU | no aplica | Reclutando pacientes | sep 2040 (prevista) |
| A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells. | no aplica | Completado | dic 2024 (real) |
Todos los de TCRX, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT06587828), actualizada en sep 2026.